EMA Accepts Pfizer s MAA For 20-valent Pneumococcal Conjugate Vaccine Candidate For Adults
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults 18 years of age and older. The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations. In many countries across Europe and around the world, more than half of all cases of invasive pneumococcal disease in older adults are due to the 20 serotypes covered in 20vPnC, including seven serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that are not included in any currently licensed pneumococcal conjugate vaccine, said Kathrin U. Jansen, Senior Vice President and Head of Vaccine Re
Date Time
Share
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years
If approved, the vaccine would help protect adults against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia
NEW YORK–(BUSINESS WIRE)– Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. With the MAA acceptance, the formal review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP) begins.
Ayn Rand once famously wrote about women saying, “The question isn’t who is going to let me; it’s who is going to stop me.” Rand may well have written these words for this pandemic. That too in a very unusual but critical vertical: C-19 vaccine research.
A number of studies in the mid-2000s revealed that almost 82% of clinical trial principal investigators in the US were men; while the coordinators, who do the really hard day-to-day slog to generate much of the knowledge and insights, were women! The situation is very different in the present scenario as there is at least one woman in a leading role for all the frontrunner Covid vaccines, the vaccine race seems to be largely driven by a powerhouse of women in their 50-60s. The woman most prominent and celebrated in her country: Major General Chen Wei, from the Chinese Academy of Military Medical Sciences, was awarded the People’s Hero title for her leadership roles in phase 3 trial in the development of Sinopharma and CanS
Endpoints News announces its Women in Biopharma 2020 winners - live event to be held today ccenterdispatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ccenterdispatch.com Daily Mail and Mail on Sunday newspapers.